In recently reports, H19 exerted two opposite effects depending on tumor types: it functioned as an oncogene in ovarian cancer [36], colorectal cancer [27], breast cancer [37] and glioblastoma [38]; whereas, it exerted tumor suppression effects in hepatocellular carcinoma [39], prostate cancer [40] and Wilms’ tumor [41]. This evidence concerns the gene H19 and prostate cancer.